Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 7:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–351 of 351 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Invasive Carcinoma of the Breast Clear all

Conditions: Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions: celecoxib, therapeutic conventional surgery, pharmacological study, laboratory biomarker analysis; Drug · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: EF5, Partial or Total Mastectomy; Drug · Procedure
Lead sponsor: Mark Dewhirst; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Newly Diagnosed Operative Invasive Ductal Breast Carcinoma Stage I-II
Interventions: Vitamin D; Dietary Supplement
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Estrogen Receptor-positive Breast Cancer, Invasive Ductal Breast Carcinoma, Invasive Ductal Breast Carcinoma With Predominant Intraductal Component, Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate, Mucinous Ductal Breast Carcinoma, Papillary Ductal Breast Carcinoma, Progesterone Receptor-positive Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Tubular Ductal Breast Carcinoma
Interventions: accelerated partial breast irradiation, intensity-modulated radiation therapy, image-guided radiation therapy, therapeutic conventional surgery; Radiation · Procedure
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 50 Years and older · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Breast Cancer, Invasive Breast Cancer, Carcinoma in Situ of the Breast
Interventions: Tissue Sample collection, Blood Sample Collection, Rectal Swab; Procedure · Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer (Triple Negative Breast Cancer (TNBC)), Renal Cell Carcinoma (Kidney Cancer), Melanoma (Skin Cancer), Non-Small Cell Lung Cancer, MSI-H/dMMR Rectal Cancer, Squamous Cell Carcinoma Mouth, Invasive Mammary Carcinoma, Classic Hodgkin Lymphoma
Interventions: Dual-Energy X-ray Absorptiometry (DXA), High Resolution peripheral Quantitative Computed Tomography (HRpQCT); Device
Lead sponsor: Jessica Mezzanotte Sharpe; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Triple Negative Breast Cancer
Interventions: Sacituzumab govitecan-hziy (SG), Pembrolizumab, Capecitabine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 1,514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 188
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 158 more

Conditions: Ductal Breast Carcinoma, Invasive Breast Carcinoma, Lobular Breast Carcinoma, Medullary Breast Carcinoma, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Tubular Breast Carcinoma
Interventions: Radiation Therapy, Questionnaire Administration, Quality-of-Life Assessment, Laboratory Biomarker Analysis, Hypofractionated Radiation Therapy; Radiation · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 898 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2035
U.S. locations: 846
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 544 more

Conditions: Breast Carcinoma, Invasive Breast Carcinoma
Interventions: Biopsy, Biospecimen Collection, Radiation Therapy; Procedure · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer, Invasive Breast Carcinoma
Interventions: Aerobic Exercise Intervention, Resistance Exercise Intervention, Exercise Intervention: Digital copies and outline of sessions, Questionnaire Administration, Quality-of-Life Assessment; Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breast Cancer
Interventions: Docetaxel, Trastuzumab, Carboplatin, Bevacizumab, 5-Fluorouracil, Epirubicin, Cyclophosphamide; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older · Female only
Enrollment: 3,509 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 393
States / cities: Birmingham, Alabama • Decatur, Alabama • Huntsville, Alabama + 272 more

Conditions: Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Breast Cancer, HER2-negative Breast Cancer, Germline BRCA1 Gene Mutation, Germline BRCA2 Gene Mutation, Deleterious PALB2 Gene Mutation
Interventions: Niraparib, Dostarlimab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 8
States / cities: New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 3 more

Conditions: Triple Negative Breast Cancer, Stage IV Breast Cancer, HER2 Negative, Invasive Breast Cancer
Interventions: Atezolizumab, Carboplatin, Laboratory Biomarker, Quality-of-Life Assessment; Drug · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Indianapolis, Indiana • Baltimore, Maryland + 3 more

Conditions: Invasive Ductal Breast Cancer, Carcinoma Breast Stage I
Interventions: Intraoperative Electron Radiotherapy; Radiation
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 50 Years to 95 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Oak Lawn, Illinois

Conditions: Breast Cancer
Interventions: Cryoablation; Procedure
Lead sponsor: Saint John's Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Santa Monica, California

Search by objective public record fields.

Celecoxib in Treating Postmenopausal Women Who Are Undergoing Surgery for Invasive Breast Cancer

To Evaluate the Characteristics of a Breast Cancer

Vitamin D3 (Vit D3) Supplementation and T Cell Immunomodulation in Patients With Newly Diagnosed Operative Invasive Ductal Breast Carcinoma

Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer

Prospective Breast Cancer Biospecimen Collection

Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer

Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer

Adaptive Training Exercise Programs for Improving Cardiorespiratory Fitness After Breast Cancer Treatment, The ACTIVATE Trial

BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer

Lumpectomy Followed By Intraoperative Electron Radiation Therapy (IOERT)

Anti-Tumor Immunity Induced by Cryoablation of Invasive Breast Cancers